GE HealthCare Technologies stock surges on FDA approval and acquisition momentum amid undervaluation debate

GE HealthCare Technologies stock jumped 3.49% in mid-day trading on the NASDAQ exchange in USD, reaching an intraday high of $72.48 on March 23, 2026. This move follows the FDA's 510(k) clearance for the company's Photonova Spectra photon-counting CT system on March 20, marking a key entry into the multi-year CT replacement cycle. Stifel reiterated its Buy rating with a $98 price target, highlighting the technology's potential to drive mid-single-digit revenue growth from 2027 onward. For US investors, this dip to around $71-72 levels represents a compelling entry point in a resilient medtech leader with strong backlog and easing tariff pressures.

As of: 23.03.2026

By Dr. Elena Voss, Senior MedTech Analyst – GE HealthCare's innovation pipeline, including photon-counting CT and AI integrations, positions it as a frontrunner in precision diagnostics amid shifting healthcare demands.

Recent Catalysts Ignite Momentum

The FDA approval of the Photonova Spectra system allows GE HealthCare to commercialize its silicon-based photon-counting CT technology in the US market. This advancement promises superior image quality and lower radiation doses, addressing key clinician demands in diagnostic imaging. Stifel analysts, after physician discussions, emphasized its role in accelerating revenue growth.

On March 18, GE HealthCare completed its acquisition of Intelerad, bolstering its cloud radiology capabilities. This move aligns with the precision-care shift, enhancing data management and AI tool integration. Combined with fresh FDA clearances for next-gen viewers and HIMSS showcase highlights, these developments signal robust product momentum.

Financially, FY2025 showed $20.6 billion in revenue, up 4.8% reported and 3.5% organic, with adjusted EPS at $4.59 and 15.3% adjusted EBIT margin. Q4 delivered 4.8% organic growth and a record $21.8 billion backlog. For 2026, guidance calls for 3-4% organic revenue growth, margins of 15.8-16.1%, and EPS of $4.95-$5.15, exceeding consensus estimates.

Official source

Stock Performance and Valuation Snapshot

Trading around $71 on NASDAQ in USD as of mid-March 2026, GE HealthCare Technologies stock sits 14-20% below its 52-week high but only about 25% below Wall Street's average target of $93. The year-to-date pullback appears tied to tariff concerns, now easing with lower 2026 guidance on that front. Forward P/E stands at approximately 14, attractive for a high-quality medtech name with visible growth.

Analyst consensus leans toward Moderate Buy, with 6 Buy and 6 Hold ratings from 12 analysts. Average price targets range from $85.20 to $92.17, implying 9-23% upside from recent levels. Recent actions include Stifel's $98 target post-FDA news and Citi's neutral stance with $84 target after Q4 adjustments.

The stock's resilience shines through a solid return on equity near 24%, efficient capital use, and strong free cash flow of $1.5 billion. A quarterly dividend of $0.035 per share underscores shareholder commitment, yielding about 0.20% annualized.

Sentiment and reactions

Competitive Edge in Medical Imaging

GE HealthCare holds a strong position in the imaging oligopoly, trading at a valuation discount to peers while showing faster organic momentum. Its record backlog and innovation pipeline, including AI-powered ultrasound via a $35 million BARDA contract expansion, differentiate it. The ReadyFix remote fleet management for ECG devices further supports cardiac care uptime.

In comparison to rivals, GEHC's tariff risk diminishes heading into 2026, paired with superior backlog quality. Photon-counting CT positions it for the replacement cycle, where demand for advanced diagnostics surges. Analysts view this as a value-plus-growth play in healthcare equipment.

Sector dynamics favor leaders like GE HealthCare, with emphasis on order intake, backlog quality, pricing power, and margin expansion. Organic growth stability and clean balance sheet provide a moat against cyclical pressures.

Why US Investors Should Watch Closely

US investors stand to benefit from GE HealthCare's US-centric revenue exposure and regulatory wins like the FDA clearance. The stock's undervaluation per InvestingPro metrics lists it among top opportunities. With a stable price around $72.86 recently on NASDAQ in USD versus a one-year high of $94.80, recovery potential appeals to those seeking medtech exposure.

Broader sector strength persists despite volatility, as noted by Citi. Institutional interest grows with steady compounding via cash flow and dividends. For portfolios balancing growth and value, GEHC offers efficiency in shareholder returns.

Photon-counting tech and cloud integrations tap into AI-driven healthcare trends, crucial for long-term US market dominance. Easing macro headwinds like tariffs enhance appeal now.

Further reading

Risks and Open Questions Ahead

While momentum builds, tariff remnants and sector volatility pose risks. Citi's price target cut to $84 reflects Q4 adjustments across medtech. Execution on new product launches, including commercialization ramps, remains key.

Competition intensifies in AI and cloud radiology, requiring sustained R&D investment. Backlog conversion into revenue depends on global demand stability. Investors should monitor 2026 guidance delivery amid potential economic shifts.

Overall, the risk-reward skews positive with analyst upgrades outweighing holds. Undervaluation provides a buffer, but patience suits this compounding story.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.